UNLIMITED TURBO SHORT - ELI LILLY & CO | Delayed Börse Stuttgart 08:35:00 27/06/2024 BST | ||
| 2.57 EUR | -14.05% |
|
| Current month | -69.61% | ||
| 1 month | -71.63% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 27/06/24 | 2.57 | -14.05% |
| 26/06/24 | 2.99 | +6.79% |
| 25/06/24 | 2.8 | -19.31% |
| 24/06/24 | 3.47 | -15.57% |
| 21/06/24 | 4.11 | -9.27% |
Delayed Quote Börse Stuttgart
Last update June 27, 2024 at 08:35 am
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PC68PU |
| ISIN | DE000PC68PU2 |
| Date issued | 25/03/2024 |
| Strike | 921.9 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 13.45 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 18.86 € |
|---|---|
| Lowest since issue | 2.26 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
901.3
USD
Average target price
860.5
USD
Spread / Average Target
-4.52%
- Stock Market
- Certificates
- Certificat
